Orchestra BioMed Holdings (OBIO)
NASDAQ:OBIO
Want to see OBIO full AI Analyst Report?
OBIO Stock Chart & Stats
$4.57
-$0.06(-1.07%)
At close: 4:00 PM EST
$4.57
-$0.06(-1.07%)
Day’s Range― - ―
52-Week Range$2.20 - $5.42
Previous CloseN/A
Volume15.92K
Average Volume (3M)176.05K
Market Cap
$267.44M
Enterprise Value$259.34M
Total Cash (Recent Filing)$106.51M
Total Debt (Recent Filing)$32.44M
Price to Earnings (P/E)―
Beta1.82
Next Earnings
May 18, 2026EPS Estimate
-0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.12
Shares Outstanding58,520,900
10 Day Avg. Volume109,373
30 Day Avg. Volume176,051
Financial Highlights & Ratios
PEG Ratio90.81
Price to Book (P/B)2.51K
Price to Sales (P/S)4758.67
P/FCF Ratio-3.22K
Enterprise Value/Market Cap0.97
Enterprise Value/Revenue7.75
Enterprise Value/Gross Profit7.79
Enterprise Value/Ebitda-5.05
Forecast
1Y Price Target
$14.25Price Target Upside211.82% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.77
Revenue Forecast (FY)$1.68M
Bulls Say, Bears Say
Bulls Say
Clinical Trial EnrollmentAccelerated enrollment in the BACKBEAT study after protocol amendments increases the likelihood of timely data readouts and could clarify the regulatory path for the AVIM pacemaker-based therapy.
Regulatory Validation Via Head-to-head TrialA U.S. pivotal trial comparing Virtue Sirolimus AngioInfusion Balloon against the only FDA-approved drug-coated balloon offers a direct pathway to regulatory approval and market validation if clinical results demonstrate competitive benefit.
Strategic Partnership And FinancingA termination and right of first refusal agreement with Terumo provides preferred access to distribution or licensing options for Virtue SAB and includes an investment commitment that strengthens funding and commercial prospects.
Bears Say
Regulatory Milestone RequirementFDA expectation for twelve-month follow-up data from the BACKBEAT trial creates a mandatory milestone that must be achieved for approval, extending the development timeline and increasing regulatory risk.
Revenue Sustainability ConcernsRecent revenue outperformance was driven by one-time transactions and similar partnership payments are not expected to recur, leaving mostly modest recurring product sales and greater uncertainty around future revenue growth.
Orchestra BioMed Holdings News
OBIO FAQ
What was Orchestra BioMed Holdings’s price range in the past 12 months?
Orchestra BioMed Holdings lowest stock price was $2.20 and its highest was $5.42 in the past 12 months.
What is Orchestra BioMed Holdings’s market cap?
Orchestra BioMed Holdings’s market cap is $267.44M.
When is Orchestra BioMed Holdings’s upcoming earnings report date?
Orchestra BioMed Holdings’s upcoming earnings report date is May 18, 2026 which is in 31 days.
How were Orchestra BioMed Holdings’s earnings last quarter?
Orchestra BioMed Holdings released its earnings results on Mar 12, 2026. The company reported $0.118 earnings per share for the quarter, beating the consensus estimate of -$0.378 by $0.496.
Is Orchestra BioMed Holdings overvalued?
According to Wall Street analysts Orchestra BioMed Holdings’s price is currently Undervalued.
Does Orchestra BioMed Holdings pay dividends?
Orchestra BioMed Holdings does not currently pay dividends.
What is Orchestra BioMed Holdings’s EPS estimate?
Orchestra BioMed Holdings’s EPS estimate is -0.43.
How many shares outstanding does Orchestra BioMed Holdings have?
Orchestra BioMed Holdings has 58,520,900 shares outstanding.
What happened to Orchestra BioMed Holdings’s price movement after its last earnings report?
Orchestra BioMed Holdings reported an EPS of $0.118 in its last earnings report, beating expectations of -$0.378. Following the earnings report the stock price went down -4.783%.
Which hedge fund is a major shareholder of Orchestra BioMed Holdings?
Currently, no hedge funds are holding shares in OBIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Orchestra BioMed Holdings Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.25 (211.82% Upside)
$14.25 (211.82% Upside)
Blogger Sentiment
Neutral
OBIO Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 165.3K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $42.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 7.4%
Last 30 Days ▲ 14.3%
Last 30 Days ▲ 14.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
62.05%
12-Months-Change
Fundamentals
Return on Equity
-169.64%
Trailing 12-Months
Asset Growth
50.78%
Trailing 12-Months
Company Description
Orchestra BioMed Holdings
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
OBIO Stock 12 Month Forecast
Average Price Target
$14.25
▲(211.82% Upside)
Technical Analysis
Cardiff Oncology
―
Greenwich LifeSciences
―
Climb Bio
―
Cognition Therapeutics
―
Pyxis Oncology
―
Ownership Overview
29.69% Insiders
3.87% Mutual Funds
27.30% Other Institutional Investors
35.55% Public Companies and
Individual Investors